Bank of New York Mellon
SLDB icon

Bank of New York Mellon’s Solid Biosciences SLDB Stock Holding History

Bank of New York Mellon’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Buy
243,154
+105,210
+76% +$798K ﹤0.01% 2831
2026
Q1 		$993K Sell
137,944
-6,755
-5% -$43.4K ﹤0.01% 3210
2025
Q4 		$816K Sell
144,699
-3,961
-3% -$21.5K ﹤0.01% 3348
2025
Q3 		$917K Sell
148,660
-9,694
-6% -$56.7K ﹤0.01% 3257
2025
Q2 		$771K Buy
158,354
+106,043
+203% +$375K ﹤0.01% 3266
2025
Q1 		$194K Buy
52,311
+241
+0.5% +$1.03K ﹤0.01% 3894
2024
Q4 		$208K Hold
52,070
– – ﹤0.01% 3937
2024
Q3 		$363K Sell
52,070
-17,037
-25% -$138K ﹤0.01% 3672
2024
Q2 		$392K Buy
+69,107
New +$619K ﹤0.01% 3698
2022
Q4 		– Sell
-3,057
Closed -$21K – 4543
2022
Q3 		$21K Hold
3,057
– – ﹤0.01% 4452
2022
Q2 		$28K Sell
3,057
-9,836
-76% -$102K ﹤0.01% 4454
2022
Q1 		$232K Sell
12,893
-329
-2% -$5.8K ﹤0.01% 4164
2021
Q4 		$347K Buy
13,222
+27
+0.2% +$825 ﹤0.01% 4016
2021
Q3 		$473K Buy
13,195
+2,283
+21% +$96.9K ﹤0.01% 3843
2021
Q2 		$599K Buy
10,912
+4,730
+77% +$312K ﹤0.01% 3688
2021
Q1 		$513K Sell
6,182
-579
-9% -$64.1K ﹤0.01% 3672
2020
Q4 		$769K Buy
6,761
+1,490
+28% +$94.2K ﹤0.01% 3400
2020
Q3 		$161K Buy
5,271
+33
+0.6% +$1.26K ﹤0.01% 3889
2020
Q2 		$230K Sell
5,238
-330
-6% -$13.7K ﹤0.01% 3762
2020
Q1 		$199K Buy
5,568
+701
+14% +$34.7K ﹤0.01% 3739
2019
Q4 		$324K Buy
4,867
+248
+5% +$27.4K ﹤0.01% 3773
2019
Q3 		$716K Sell
4,619
-131
-3% -$14.8K ﹤0.01% 3352
2019
Q2 		$410K Buy
4,750
+1,272
+37% +$139K ﹤0.01% 3695
2019
Q1 		$480K Sell
3,478
-302
-8% -$75.7K ﹤0.01% 3572
2018
Q4 		$1.52M Buy
3,780
+995
+36% +$468K ﹤0.01% 2870
2018
Q3 		$1.97M Buy
2,785
+659
+31% +$414K ﹤0.01% 2839
2018
Q2 		$1.14M Buy
2,126
+782
+58% +$241K ﹤0.01% 3183
2018
Q1 		$152K Buy
+1,344
New +$454K ﹤0.01% 3985

Other funds holding SLDB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon's SLDB Position: Q2 2026 in Review

Bank of New York Mellon increased its Solid Biosciences (SLDB) stake by 76% in Q2 2026, buying an estimated $798K and bringing the position to 243,154 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2831.

Bank of New York Mellon first reported a position in SLDB in Q1 2018 and has held it in 28 quarters since. 37 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Bank of New York Mellon held 243,154 shares of Solid Biosciences worth $2.43M as of Q2 2026.
  • Bank of New York Mellon bought 105,210 Solid Biosciences shares in Q2 2026, an estimated $798K.
  • Solid Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2831 holding.
  • Bank of New York Mellon first reported a position in Solid Biosciences in Q1 2018 and has held it in 28 quarters since.
  • 37 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.